A Randomized, Placebo-controlled,Observer-blinded Study, To Evaluate Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of RO7239958 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs RO 7239958 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 31 Oct 2019 Planned number of patients changed from 75 to 82.
- 31 Oct 2019 Planned End Date changed from 20 Nov 2021 to 13 Mar 2021.
- 31 Oct 2019 Planned primary completion date changed from 20 Nov 2021 to 13 Mar 2021.